Attitudes Toward Proactive Topical Corticosteroid Use Among Women With Vulval Lichen Sclerosus

J Low Genit Tract Dis. 2024 Apr 1;28(2):183-188. doi: 10.1097/LGT.0000000000000791.

Abstract

Objectives: Some practitioners are adopting proactive topical corticosteroid (TCS) therapy for vulval lichen sclerosus (VLS). We sought to understand patient attitudes toward proactive TCS therapy for VLS in a context in which proactive therapy is adopted.

Methods: Four online focus group discussions with 12 participants. Data analysis was informed by social constructionist grounded theory.

Results: All participants had accepted a proactive regimen. Three themes were developed from the analysis: "Coming to accept proactive therapy," "Motivators to maintaining a proactive regimen," and "The importance of a routine that fits me." Within each theme are subthemes illustrating different dimensions of the theme.

Conclusions: Accepting proactive TCS therapy for VLS requires incorporating regular TCS use into a patient's identity, unlearning previous understandings regarding the safety of long-term TCS use, and adopting a regimen that fits within patients' lives and minimizes the loss of autonomy.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Dermatologic Agents*
  • Female
  • Glucocorticoids
  • Humans
  • Lichen Sclerosus et Atrophicus* / drug therapy
  • Vulvar Lichen Sclerosus* / drug therapy

Substances

  • Glucocorticoids
  • Adrenal Cortex Hormones
  • Dermatologic Agents